Sequence determinants of modified cobra venom neurotoxin which induce immune resistance to experimental allergic encephalomyelitis: Molecular mechanisms for immunologic action

Immunopharmacology and Immunotoxicology

Volumn 21, Issue 3, 1999, Pages 483-506

  Hinman, Channing L ^a   Stevens Truss, Regina ^a   Schwarz, Christopher ^a   Hudson, Richard A ^a,b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

Cobratoxin derivative; Experimental allergic encephalomyelitis; Immunosuppressive

Indexed keywords

CARDIOTOXIN; CYTOCHROME C; FREUND ADJUVANT; IODOACETAMIDE; MYELIN BASIC PROTEIN; NEUROTOXIN; SNAKE VENOM; SODIUM CHLORIDE; TRYPSIN;

ALLERGIC ENCEPHALOMYELITIS; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG MECHANISM; GUINEA PIG; IMMUNITY; INTRADERMAL DRUG ADMINISTRATION; LYMPHOCYTIC INFILTRATION; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; SEQUENCE HOMOLOGY; TOXIN STRUCTURE;

ANIMALIA; CAVIA; CAVIA PORCELLUS; SERPENTES; SUS SCROFA;

EID: 0032820260     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979909007122     Document Type: Article

References (54)

1. Roboz-Einstein, E., Csejty, J., Davis, W. I. and Rauch, H. C., Protective action of the encephalitogen and other basic proteins in experimental allergic encephalomyelitis, Immunochem., 5:567, 1968.
2. Stone, S. H. and Lerner, E. M., Chronic disseminated allergic encephalomyelitis in guinea pigs, Ann. N.Y. Acad. Sci., 122:227, 1965.
3. Alvord, E. C., Jr., Shaw, C. M., Hruby, S. and Kies, M. W., Encephalitogen-induced inhibition of experimental allergic encephalomyelitis: prevention, suppression and therapy, Ann. N.Y. Acad. Sci., 122:333, 1965.
4. Field, E. J. and Caspary, E. A., Protective effect of encephalitogenic factor in experimental allergic encephalomyelitis, Nature, 201:936, 1964.
5. Hashim, G. A. and Shilling, F. J., Allergic Encephalomyelitis: Characterization of the determinants for delayed type hypersensitivity, Biochem. Biophys. Res. Comm., 50:589, 1973.
6. Hashim, G. A., Sharpe, R. D. Carvalho, E. F. and Stevens, L. E., Suppression and reversal of allergic encephalomyelitis in guinea pigs with a non-encephalitogenic analogue of the tryptophan region of the myelin basic protein, J. Immunol., 116:126, 1976.
7. Hashim, G. A., Myelin basic protein-Structure, function and antigenic determinants, Immunol. Rev., 39:60, 1978.
8. Kies, M. W. and Alvord, E. C., Jr., Prevention of allergic encephalomyelitis by prior injection of adjuvants, Nature, 182:1106, 1958.
9. Lisak, R. P., Zweiman, B., Blanchard, N. and Borke L. B., Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE), J. Neurol. Sci., 62:281, 1983.
10. Lyman, W. D., Kadish, A. S., Brosnan, C. F. and Raine, C. S., Antigen-induced suppression of mitogen responses and resistance to experimental allergic encephalomyelitis, Cell. Immunol., 78:43, 1983.
11. Montgomery, I. N. and Rauch, H. C., Bovine-derived spinal cord protein (SCP) protects guinea pigs from experimental allergic encephalomyelitis (EAE) - A confirmatory report, Immunol. Comm., 9:289, 1980.
12. Nagai, Y., Osanai, T. and Sakakibara, K., Intensive suppression of experimental allergic encephalomyelitis (EAE) by serum thymic factor and therapeutic implication for multiple sclerosis, Japan J. Exp. Med., 52:213, 1982.
13. Rauch, H. C., Montgomey, I. N. and Swanborg, R. H., Inhibition of experimental allergic encephalomyelitis by carrier administered prior to challenge with encephalitogenic peptide-carrier conjugate, Eur. J. Immunol., 11:335, 1981.
14. Rauch, H. C. and Roboz-Einstein, E., Induction and suppression of experimental allergic encephalomyelitis in non-human primates, J. Neurol. Sci., 23:99, 1974.
15. Roboz-Einstein, E., Chao, L.-P., Csejty, J., Kibler, R. and Shapira, R., Species specificity in response to tryptophan modified encephalitogen, Immunochem., 9:73, 1972.
16. Roboz-Einstein, E., Chao, L.-P. and Csejty, J., Suppression of experimental allergic encephalomyelitis by chemically modified encephalitogen, Immunochem., 9:1013, 1972.
17. Shaw, C. M., Fahlberg, W. J., Kies, M. W. and Alvord, E. C., Jr., Suppression of experimental "allergic" encephalomyelitis in guinea pigs by encephalitogenic proteins extracted from homologous brain, J. Exp. Med., 111:171, 1960.
18. Swanborg, R. H., Antigen-induced inhibition of experimental allergic encephalomyelitis. 1. Inhibition in guinea pigs injected with non-encephalitogenic modified myelin basic protein, J. Immunol., 109:540, 1972.
19. Swanborg, R. H., Antigen-induced inhibition of experimental allergic encephalomyelitis. III. Localization of an inhibitory site distinct from the major encephalitogenic determinant of myelin basic protein, J. Immunol., 114:191, 1975.
20. Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R. and Sela, M., Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide, Eur. J. Immunol., 1:242, 1971.
21. Webb, C., Teitelbaum, D., Herz, A., Arnon, R. and Sela, M., Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids, Immunochem., 13:333, 1976.
22. Bitar, D. M., and Whitaker, C. C., Suppression of experimental autoimmune encephalitis by the oral administration of myelin basic protein, Cell. Immunol., 112:364, 1988.
23. Higgens, P. J. and Weiner, H. L., Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments, J. Immunol., 140:440, 1988.
24. Lider, O., Santos, L. M. B., Lee, C. S. Y., Higgins, P. J. and Weiner, H. L. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. J. Immunol. 1989; 142, 748-752.
25. Fuller, K. A., Pearl, D. and Whitacre, C. C., Oral tolerance in experimental autoimmune encephalomyelitis: serum and salivary antibody responses, J. Neuroimmunol., 28:15, 1990.
26. Whitacre, C. C., Gienapp, I. E., Orosz, C. G. and Bitar, D. M., Oral tolerance in experimental autoimmune encephalomyelitis III. Evidence for clonal anergy, J. Immunol., 147:2155, 1991.
27. Whitacre, C. C., Gienapp, I. E., Meyer, A., Cox, K. L. and Javed, N., Treatment of autoimmune disease by oral tolerance to autoantigens, Clin. Immunol. Immunopathol., 80:S31, 1996.
28. Shaw, C., Alvord, E. C., Jr., Kaku, J. and Kies, M. W., Correlation of experimental allergic encephalomyelitis with delayed-type skin sensitivity to specific homologous encephalitogen, Ann. N.Y. Acad. Sci., 122:318, 1965.
29. Hudson, R. A. Montgomery, I. N. and Rauch, H. C., Experimental allergic encephalomyelitis: prevention with a nontoxic derivative of a cobra neurotoxin, Mol. Immunol., 20:229, 1983.
30. Zusman, N., Cafmeyer, N. and Hudson, R. A., Purification and characterization of the cardiotoxins from the venom of Thailand cobra, Naja naja siamensis, Comp. Biochem. Physiol., 69B:345, 1981.
31. Nickoloff, B. J., Grimes, M., Wohlfeil, E. R. and Hudson, R. A., Affinity-dependent cross-linking to neurotoxin sites of the acetylcholine receptor mediated by catechol oxidation, Biochemistry, 24:999, 1985.
32. Crestfield, A. M., Moore, S. and Stein, W. H., The preparation and enzymatic hydrolysis of reduced and S-carboxymethylated proteins, J. Biol. Chem., 238:622, 1963.
33. Wohlfeil, E. R. and Hudson, R. A., Synthesis and characterization of a heterobifunctional mercurial cross-linking agent: incorporation into cobratoxin and interaction with the nicotinic acetylcholine receptor, Biochemistry, 30:7231, 1991.
34. Nakao, A., Davis, W. J. and Einstein, E. R., Basic proteins from acidic extracts of bovine spinal cord - Isolation and characterization, Biochim. Biophys. Acta, 130:163, 1965.
35. Hinman, C. L., Rauch, H. and Pfeiffer, R., Application of high performance liquid chromatography to the preparation of encephalitogenic myelin basic protein, Life Sci., 30:989, 1982.
36. Groome, N. P., Enzyme-linked immunoadsorbent assays for myelin basic protein and antibodies to myelin basic protein, J. Neurochem., 35:1409, 1980.
37. Rauch, H. C., Montgomery, I. N., Hinman, C. L. and Harb, W., Experimental allergic encephalomyelitis in mice: Presence of myelin basic protein in cerebrospinal fluid, J Neuroimmunol., 15:73, 1987.
38. Karlsson, E., Arnberg, H. and Eaker, D., Isolation of the principal neurotoxins of two Naja naja subspecies, Eur. J. Biochem., 21:1, 1971.
39. Harvey, A. L., Marshall, R. J. and Karlsson, E., Effects of purified cardiotoxins from the Thailand cobra (Naja naja siamensis) on isolated skeletal and cardiac muscle preparation, Toxicon, 20:379, 1982.
40. Zusman, N., Miklas, T. M., Graves, T., Dambach, G. E. and Hudson, R. A., On the interaction of cobra venom protein cardiotoxins with erythrocytes, Biochem. Biophys. Res. Comm., 124:629, 1984.
41. Oldstone, M. B. A. Molecular mimicry and immune-mediated diseases, FASEB J., 12;1255, 1998.
42. Tsernoglou, D., Petsko, G. A. and Hudson, R. A., Structure and function of snake venom alpha-neurotoxins, Molec. Pharmacol., 14:710, 1978.
43. Basus, V. J., Song, G. and Hawrot, E., NMR solution structure of an α-bungarotoxin/nicotinic acetylcholine receptor peptide complex, Biochemistry, 32:12290, 1993.
44. Karlsson, E., Chemistry of protein toxins in snake venoms, In Handbook of Experimental Pharmacology, edited by C. Y. Lee, Vol. 52, p. 159, Springer-Verlag, Berlin, 1979.
45. Webb, D. R., Mensi, N., Freire-Moar, J., Schnaper, H. W., Lewis, R. V., Semenuk, G., Devens, B. H., Koontz, A., Danho, W., Pan, Y.-C., Wesselschmidt, R., Aune, T. M. and Pierce, C. W., Putative N-terminal sequence of murine soluble immune response suppressor (SIRS): significant homology with short neurotoxin 1, Inter. Immunol., 2:765, 1990.
46. Waksman, B., Neuroimmunomodulation of homeostasis and host defense, J. Immunol., 135:862s, 1985.
47. Selsted, M. E., Brown, D. M., Delange, R. J., Harwig, S. S. L. and Lehrer, R. I., Primary structure of six antimicrobial peptides of rabbit peritoneal neutrophils, J. Biol. Chem., 260:4579, 1985.
48. Howell, M. D., Winters, S. T., Olee, T., Powell, H. C., Carlo, D. J. and Brostoff, S. W., Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides, Science, 246:668, 1989.
49. Offner, H., Hashim, G. A. and Vandenbark, A. A., T -Cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis, Science, 251:430, 1991.
50. β usage to immunodominant regions of myelin basic protein, Science, 248:1016, 1990.
51. Critchfield, J. M., Racke, M. K., Zuniga-Pflucker, J. C., Cannella, B., Raine, C. S., Goverman, J. and Lenardo, M. J., T-cell deletion in high antigen dose therapy of autoimmune encephalomyelitis, Science, 263:1139, 1994.
52. Allegretta, M., Nicklas, J. A., Sriram, S. and Albertine, R. J. T-cells responsive to myelin basic protein in patients with multiple sclerosis, Science, 247:718, 1990.
53. Gaur, A., Wiers, B., Liu, A. Rothbard, J. Fathman, C. G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy, Science, 258:1491, 1992.
54. Arnon, R. and van Regenmortel, M. H. V., Structural basis of antigenic specificity and design of new vaccines, FASEB J., 6:3265, 1992.